MGC Pharma has received formal notification of the acceptance of its patent application for its self-nanoemulsifying drug delivery system by the Slovenian Intellectual Property Office (SIPO).
The successful patent application of European-based biopharma company MGC Pharma for the Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System (SNEDDS) now gives the Company priority to file subsequent patent applications for the product in other jurisdictions and Intellectual Property (IP) agencies.
MGC Pharma anticipates that the patent for its novel SNEDDS formulation will be issued within the coming 12 months.
The application sets out the formulation of the SNEDDS, as well as the method of manufacture and its capacity for enhancing stability, solubility and bioavailability of drugs that are designed for multiple neurological therapeutic applications.
Traditionally, cannabidiol (CBD) has been administered in either oil- or alcohol-based formulations which vary greatly in bioavailability. MGC Pharma’s SNEDDS enables the administration of higher concentrations of CBD, at 100-200 milligrams per ML, needed for the treatment of neurological conditions at increased bioavailability.
The molecule emulsifies immediately at the oral mucosa epithelium, resulting in instant bio-trade into the blood plasma.
The SNEDDS is based on the Type IV (oil-free) nanotechnology which guarantees a globular molecule size below 50 nanometres in order to pass through the Blood Brain Barrier for the treatment of neurological diseases, and is based on an “Ionic Complex” that greatly increases solubility and bioavailability of the Active Pharmaceutical Ingredient (API).
MGC Pharma is looking to implement this delivery system in its CannEpilTM and CogniCannTM products, both of which are going through the clinical development process, including clinical trials.
CBD as a neurological treatment
CBD has demonstrated beneficial effects in clinical studies and has been found to have antioxidative, anti-inflammatory, and neuroprotective properties. It has also become a supplemental therapy for a number of neurological conditions including multiple sclerosis, neurodegenerative disorders (such as Parkinson’s disease, Huntington’s disease, Tourette’s syndrome and Alzheimer’s disease), epilepsy, chronic pain, neuralgia and various psychiatric disorders.
Roby Zomer, co-founder and managing director of MGC Pharma, commented: “The acceptance of this patent could be transformational for patients who need treatment and therapeutic relief from neurological diseases. The new IP will not only improve MGC Pharma’s current formulations, including our phytocannabinoid-based drugs CannEpilTM and CogniCannTM, but potentially provide more affordable medicines for patients as a result of the more efficient use of resources in formulations.
“The submission to SIPO provides MGC Pharma with the right to file further applications in multiple jurisdictions and treat people and patients suffering from these conditions on a global scale.”